Trade Mark Journal No.2026/039 25 September 2026

WO0000001936962 (5)

Office of origin: United States of America

Date of International Registration:29 July 2026
Date of designation in the UK: 29 July 2026
Image for mark 1936962 MELPIDRA

International priority date claimed: 4 February 2026 (United States of America) (99633198)
Class 5
Pharmaceutical preparations for gene therapy for the treatment of progressive genetic neurological disorders, neurogenetic diseases, neurodegenerative diseases.

Elpida Therapeutics

Representative: Caroline E. Bryce Sheridan Ross P.C., 1560 Broadway, Suite 1200, Denver CO 80202, UNITED STATES OF AMERICA